Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 2184 • ACR Convergence 2024
Loss to Follow up After Transfer from Pediatric to Adult Care in Patients with JIA or jSLE
Simran Heera¹, Matthew Sholdice², Tania Cellucci³, Stephanie Garner⁴, Liane Heale⁵, Mark Matsos⁶, KAREN BEATTIE⁷ and Michelle Batthish³, ¹McMaster University, Mississauga, ON, Canada, ²McMaster University, London, ON, Canada, ³McMaster Children's Hospital, Hamilton, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵McMaster University, Oakville, ON, Canada, ⁶McMaster Lupus Clinic, Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON, Canada, ⁷McMaster University, Hamilton, ON, Canada
Background/Purpose: In Canada, adolescents with JIA and jSLE transfer from pediatric to adult care around age 18. This vulnerable transition period is associated with an…
Abstract Number: 0381 • ACR Convergence 2024
Two- and 3-Year Outcomes of the Childhood Arthritis and Rheumatology Research Alliance FROST Study of New-onset Systemic JIA Treatment
Timothy Hahn¹, George Tomlinson², Yukiko Kimura³, Vincent Del Gaizo⁴, Carlos Valdes⁵ and Timothy Beukelman⁶, and for the CARRA FROST Investigators, ¹Penn State Childrens Hospital, Hershey, PA, ²University of Toronto, Toronto, ON, Canada, ³Hackensack Meridian School of Medicine, New York, NY, ⁴Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁵Genentech, Davie, FL, ⁶University of Alabama at Birmingham, Birmingham, AL

Background/Purpose: The FiRst Line Options for sJIA Treatment (FROST) trial was a prospective observational study designed to compare the effectiveness of 4 Childhood Arthritis and…
Abstract Number: 0405 • ACR Convergence 2024
Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial
Ekaterina Alexeeva¹, Tatiana Dvoryakovskaya², Elena Zholobova³, Elizaveta Krekhova⁴, Rinat Raupov⁵, Daria Bukhanova⁶, Alina Egorova⁶, Sofia Kuzkina⁶, Mikhail Samsonov⁶, Irina Nikishina⁷ and Mikhail Kostik⁵, ¹National Medical Research Center of Children's Health, Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ²National Medical Research Center of Children's Health, Moscow, Russia, ³Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ⁴National Medical Research Centre for Children's Health, Moscow, Russia, ⁵Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia, ⁶R-Pharm, Moscow, Russia, ⁷V. A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 inhibitor for treatment of rheumatoid arthritis and is being investigated in the open-label Phase 2 trial in adolescents…
Abstract Number: 1117 • ACR Convergence 2024
JAK Inhibitor Therapy in Refractory Uveitis Due to Immune-mediated Inflammatory Disorders. Multicenter Study and Literature Review
Nuria Barroso Garcia¹, Lara Sanchez Bilbao², Jose Luis Martin Varillas³, Vanesa Calvo-Rio⁴, Mar Esteban Ortega⁵, Santiago muñoz Fernández⁵, Jose Luis álvarez Vega⁶, Emma Beltran Catalan⁷, Vega Jovani⁸, Olga Maiz Alonso⁹, Raúl Veroz González¹⁰, Carmen Alvarez Reguera¹¹, Rosalia Demetrio Pablo¹² and Ricardo Blanco-Alonso¹³, ¹Rheumatology, Hospital Regional Universitario, Universidad de Málaga UMA, Málaga, Spain, Malaga, Spain, ²Rheumatology and Ophthalmology. Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology. Hospital de Laredo. IDIVAL, Immunopathology Group. Laredo, Spain, Santander, Spain, ⁴Valdecilla Hospital, Santander, Cantabria, Spain, ⁵Rheumatology and Ophthalmology. Hospital Infanta Sofía, Madrid. Spain, Madrid, Spain, ⁶Rheumatology. Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, Badajoz, Spain, ⁷Rheumatology. Hospital del Mar. Barcelona, Spain, Barcelona, Spain, ⁸National Health system, Alicante, Spain, ⁹Rheumatology. Hospital de Donostia. San Sebastián, Spain, San Sebastián, Spain, ¹⁰Hospital Mérida, Badajoz, Spain, ¹¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹²Rheumatology and Ophthalmology. Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology Group. Santander. Spain, Santander, Spain, ¹³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Non-infectious uveitis refractory to conventional immunosuppressants and even biologic therapy can lead to severe ocular conditions. Janus Kinase inhibitors (JAKINIBs) appear to be effective…
Abstract Number: 2192 • ACR Convergence 2024
Utilizing Electronic Health Record Pre-Consultation Data to Create a Predictive Algorithm for Diagnosis of Chronic Pediatric Rheumatic Conditions
Kendra Lauer¹, Kyla Driest², Laura Pratt³ and Alysha Taxter², ¹Nationwide Children's Hospital, Dublin, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Nationwide Children's Hospital/The Ohio State University College of Medicine, Columbus, OH
Background/Purpose: With the current workforce shortage, wait times for initial consultation with pediatric rheumatology are lengthy and many referrals do not result in a rheumatic…
Abstract Number: 0382 • ACR Convergence 2024
Comparative Analysis of Tear-based S100 Proteins, Cytokines, and Chemokines Levels in Juvenile Idiopathic Arthritis Associated-uveitis: Insights into Eye Laterality and Severity of Ocular Inflammation
Ilaria Maccora¹, Mariia Pavlenko², Jackeline Rodriguez-Smith³, Amy Cassedy⁴, Mekibib Altaye⁵, hermine brunner⁶, Alexandra Duell⁵, Alexei Grom⁵, Theresa Hennard⁷, Virginia Miraldi Utz⁵, Najima Mwase⁵, Megan Quinlan-Waters⁵, grant schulert⁵, Alyssa Sproles⁸, Jessica Shantha⁹, Sunil K Srivastava¹⁰, Sherry Thornton⁸, Steven Yeh¹¹ and sheila Angeles-Han¹², ¹?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ²Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, ⁴Division of Biostatistics and Epidemology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁷Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁸Cincinnati Children's Hospital, Cincinnati, ⁹UCSF/Proctor Foundation, San Francisco, IL, ¹⁰Cole Eye Institute, Cleveland Clinic;, Cleveland, OH, ¹¹Truhlsen Eye Institute, University of Nebraska Medical Center., Nebraska, NE, ¹²Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is an ocular disease that can be unilateral or bilateral. Measurement of ocular inflammation is performed by ophthalmic examination…
Abstract Number: 0406 • ACR Convergence 2024
Delayed Diagnosis and Accrual of Joint Damage in Incident Cases of Juvenile Idiopathic Arthritis
Anna Costello¹, Cassandra Muir¹, Rui Xiao², Pamela Weiss³ and Irit Rasooly¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Timely diagnosis of Juvenile Idiopathic Arthritis (JIA) enables early initiation of therapy, prevents accrual of joint damage, and improves outcomes. Data regarding the diagnostic…
Abstract Number: 1233 • ACR Convergence 2024
Narrative Medicine Intervention for Mental Wellbeing in Juvenile Myositis and Juvenile Idiopathic Arthritis
Aviya Lanis¹, Emily Steelquist², Christian Lood³ and Susan Shenoi⁴, ¹Seattle Children's Hospital, Seattle, WA, ²OHSU, Portland, OR, ³Division of Rheumatology, University of Washington, Seattle, WA, Seattle, WA, ⁴Seattle Children's Hospital and Research Center, Mercer Island, WA, WA
Background/Purpose: Children with juvenile dermatomyositis (JDM) and juvenile idiopathic arthritis (JIA) have impaired quality of life and increased rates of anxiety and depression (15-65%), even…
Abstract Number: 2529 • ACR Convergence 2024
Improving Outcomes and Narrowing Disparities in Juvenile Idiopathic Arthritis (JIA): A Division-Wide, Equity-Focused Quality Improvement Project
Dori Abel¹, Kirsten Spichiger², Megan Roman², William Baar², Claire O'Malley², Jay Mehta¹, Terri Al'Hadi², Kerry Ferraro³, Denique Butler², Asia Wilson-Sanders², Catherine Lewis², Danielle Dodson⁴ and Jon Burnham¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, ³JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁴The Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: Although new therapeutics and treat-to-target interventions have improved JIA care, pronounced racial and ethnic outcome disparities persist. At our center, the mean population-level clinical Juvenile…
Abstract Number: 0383 • ACR Convergence 2024
Identification of Protein Biomarkers in Tear Fluid of Children with Uveitis That Distinguishes the Ocular Inflammatory State
Ilaria Maccora¹, hermine brunner², Mekibib Altaye³, Alexandra Duell³, Wendy Haffey⁴, Megan Quinlan-Waters³, Alyssa Sproles⁵, Sherry Thornton⁵, Virginia Miraldi Utz³, Kenneth Greis⁴ and sheila Angeles-Han⁶, ¹?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ²Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Proteomics and Mass Spectrometry, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, ⁵Cincinnati Children's Hospital, Cincinnati, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Vision loss occurs in 50% of children with chronic anterior uveitis (CAU). Lack of symptoms and overt ocular signs of inflammation may lead to…
Abstract Number: 0407 • ACR Convergence 2024
Prevalence of Autoimmune Diseases in 8244 Family Members of Children with Juvenile Idiopathic Arthritis: A Study from India
Lekshmi Minikumari Rahulan¹, Able Lawrence² and Amita Aggarwal³, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ²SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Familial aggregation of autoimmune disease as well as co-occurrence of multiple autoimmune diseases in one individual is known and it suggests a shared genetic…
Abstract Number: 1235 • ACR Convergence 2024
Rheum to Grow: Supporting Young Adults with Childhood-Onset Rheumatic Disease in Their Transition to Adult Care
Cindy Chiu¹, Sadie Van den Bogaerde², Maya Swaminathan³, Rebecca Sadun⁴ and Thomason Jenna¹, ¹University of Washington, Division of Rheumatology, Seattle, WA, ²University of Washington, Seattle, WA, ³MultiCare, Newcastle, WA, ⁴Duke University, Durham, NC
Background/Purpose: Transitional care for patients with childhood-onset rheumatic disease is essential, as this transition is known to be a high-risk time for medication nonadherence, lapses…
Abstract Number: 2570 • ACR Convergence 2024
Comparison of the Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis- Associated Lung Disease (SJIA-LD) Cohort to CARRA Registry SJIA Patients Without Lung Disease
Esraa Eloseily¹, Autumn Clark¹, Min-Lee Chang², Mary Ellen Riordan³, Alan Russell⁴, Marc Natter⁵, Scott Canna⁶, Sherry Thornton⁷, Yukiko Kimura⁸ and grant schulert¹, and CARRA FROST Investigators and the CARRA Registry SJIA-LD Cohort Investigators, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Computational Health Informatics Program, Boston Children’s Hospital, Boston, MA, ³Hackensack University Medical Center, Westwood, NJ, ⁴Duke Clinical Research Institute, Durham, NC, ⁵Boston Children's Hospital, Boston, MA, ⁶Children's Hospital of Philadelphia, Philadelphia, PA, ⁷Cincinnati Children's Hospital, Cincinnati, ⁸Hackensack Meridian School of Medicine, New York, NY
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) associated lung disease (SJIA-LD) is an emerging life-threatening disease with urgent unmet knowledge gaps. This study compares the clinical…
Abstract Number: 0384 • ACR Convergence 2024
Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study
Corey J. Bishop¹, Edwin Lam², Sophia G. Liva³, Jocelyn H. Leu², Amy S. Paller⁴, Lucia Z. Diaz⁵, Laura Wine Lee⁶, Cory Rubin⁷, Ruy Carrasco⁸, Lisa Imundo⁹, Azadeh Majlessi¹⁰, Katherine Berezny¹, Kathleen G. Lomax¹, Valerie Smith¹, Renping Zhang¹ and hermine brunner¹¹, ¹Janssen Research & Development, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, ³Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ⁴Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁵Dell Children’s Medical Center; Dell Medical School at the University of Texas at Austin, Austin, TX, ⁶Medical University of South Carolina, Charleston, SC, ⁷Michigan Dermatology Institute, Waterford, MI, ⁸Pediatric Rheumatology Consultants of Austin, Austin, TX, ⁹Columbia University Medical Center, New York, NY, ¹⁰Newport Huntington Medical Group, Huntington Beach, CA, ¹¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Ustekinumab (UST), an interleukin‑12/23p40 antagonist, is currently approved for juvenile psoriatic arthritis (jPsA) solely in the United States (US). Although a phase 3 study…
Abstract Number: 0408 • ACR Convergence 2024
Analysis of Protein Biomarkers for the Prediction of IL-1 Inhibitor Treatment Response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study
Michael Matt¹, Mariana Correia Marques², Sabrina Fuehner³, Lexi Auld¹, George Tomlinson⁴, Michael Ombrello⁵, Yukiko Kimura⁶, Christoph Kessel⁷ and grant schulert¹, and the CARRA FROST Investigators, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²National Institutes of Health, Bethesda, MD, ³Universitaetsklinikum Muenster, Muenster, Germany, ⁴University of Toronto, Toronto, ON, Canada, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁶Hackensack Meridian School of Medicine, New York, NY, ⁷University Hospital Muenster, Muenster, Germany
Background/Purpose: IL-1 inhibitors are both widely used and highly effective as first-line therapy for children with systemic juvenile idiopathic arthritis (sJIA); however, the mechanisms underlying…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].